Merck will make very, very little money off this vaccine. The effort was never about the bottom line. It was about doing what needed to be done when few others could or would. Publicly funded Canadian research deserves praise for this work. But one can and should ask why those laboratories did not finish what they started. And it’s worth noting who did.
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology